| Current Price | $28.81 | Mkt Cap | $57.8B |
|---|---|---|---|
| Open | $29.06 | P/E Ratio | 12.86 |
| Prev. Close | $29.36 | Div. (Yield) | $1.53 (5.2%) |
| Daily Range | $28.47 - $29.27 | Volume | 7,169,144 |
| 52-Wk Range | $28.47 - $58.71 | Avg. Daily Vol. | 7,568,913 |
The Company is a global healthcare group which is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter medicines and health-related consumer products.
| Current Price | $28.81 | Mkt Cap | $57.8B |
|---|---|---|---|
| Open | $29.06 | P/E Ratio | 12.86 |
| Prev. Close | $29.36 | Div. (Yield) | $1.53 (5.2%) |
| Daily Range | $28.47 - $29.27 | Volume | 7,169,144 |
| 52-Wk Range | $28.47 - $58.71 | Avg. Daily Vol. | 7,568,913 |
The best Bull and Bear pitches based on recency and number of recommendations.
Good dividends, strong company
GSK is revising Avandia product label to reflect negative events such as myocardial ischemia. Since there is no reduction in cardiovascular risks for diabetics, this reduces the long term outlook for the profitablity of this drug product and GSK.
Read the most recent pitches from players about GSK.
Recs
1russianguy
(87.08)
Submitted: 6/13/2022 11:27:59 AM :
Start Price:
$42.29
NYSE:GSK Score:
-28.87
https://www.cbsnews.com/news/rectal-cancer-drug-trial-immunotherapy-dostarlimab-study/
https://www.gsk.com/en-gb/media/press-releases/gsk-receives-fda-accelerated-approval-for-jemperli-dostarlimab-gxly-for-adult-patients-with-mismatch-repair-deficient-dmmr-recurrent-or-advanced-solid-tumours/
Recs
RES7
(94.97)
Submitted: 4/4/2022 1:20:04 AM :
Start Price:
$42.88
NYSE:GSK Score:
-13.69
sa..finaciaaly free investor
Recs
TMFjimhalley
(< 20)
Submitted: 3/21/2022 4:59:36 PM :
Start Price:
$42.70
NYSE:GSK Score:
-14.73
The company expects to increase margins after its spinoff from its consumer healthcare division. It also has a strong portfolio in oncology and an above-average dividend for a pharmaceutical company.
Find the members with the highest scoring picks in GSK.
niwhsa (84.05) Score: +301.42
The Score Leader is the player with the highest score across all their picks in GSK.
|
Top Pick |
Member Name |
Member Rating |
Start Date |
Call |
Time Frame |
Start Price |
Stock Gain |
Index Gain |
Score | Commentary |
|---|---|---|---|---|---|---|---|---|---|---|
| niwhsa | 84.05 | 11/20/2008 |
|
3Y | $17.17 | +67.50% | +368.93% | +301.42 | 0 Comment | |
| stockpickeraz | 26.46 | 1/16/2009 |
|
5Y | $18.47 | +55.73% | +341.34% | +285.61 | 0 Comment | |
| stoneyg72 | 81.82 | 4/1/2009 |
|
3W | $15.87 | +81.30% | +359.26% | +277.96 | 0 Comment | |
| lwc123 | 55.11 | 1/8/2009 |
|
3Y | $19.84 | +45.01% | +313.13% | +268.12 | 0 Comment | |
| TRGoodvsEvil | 97.97 | 7/6/2009 |
|
5Y | $17.95 | +60.27% | +313.50% | +253.24 | 0 Comment | |
| MIKEP75731 | 38.52 | 5/22/2009 |
|
5Y | $17.21 | +67.14% | +315.50% | +248.36 | 1 Comment | |
| longterm007 | 89.48 | 10/31/2008 |
|
5Y | $19.53 | +47.26% | +294.53% | +247.27 | 0 Comment | |
| janiceelaine | < 20 | 10/6/2008 |
|
3Y | $21.33 | +34.88% | +250.46% | +215.58 | 0 Comment | |
| PurePwnage | 96.78 | 11/27/2009 |
|
5Y | $22.11 | +30.10% | +237.65% | +207.55 | 0 Comment | |
| allmymarbles | 62.89 | 2/19/2010 |
|
5Y | $20.60 | +39.65% | +230.87% | +191.22 | 0 Comment |
See what the Wall Street professionals think, according to their public statements and filings.
